Tumor Bacteria Inspire New Cancer Treatment That Starves Tumors of Energy
A bacterial peptide called aurB targets mitochondria in cancer cells, cutting off their energy supply in preclinical prostate cancer studies.
Summary
Researchers at the University of Illinois Chicago developed a new experimental cancer treatment derived from bacteria that naturally live inside tumors. The peptide, called aurB, is inspired by a bacterial protein called auracyanin and works by infiltrating cancer cells and disrupting their mitochondria — the energy-producing structures that aggressive tumors depend on. Unlike earlier treatments that relied on the p53 gene, which is frequently mutated in cancer patients, aurB operates independently of p53, potentially making it effective for a broader range of patients. In preclinical studies, aurB showed strong results in hormone therapy-resistant prostate cancer models, especially when combined with radiation. The findings were published in Signal Transduction and Targeted Therapy.
Detailed Summary
Cancer cells are energy-hungry — they grow fast and rely heavily on mitochondria to fuel that growth. A new experimental therapy exploits that dependency by using a peptide derived from bacteria found living inside tumors themselves. Researchers at the University of Illinois Chicago have developed this peptide, called aurB, which targets ATP synthase inside cancer cell mitochondria, effectively cutting off the tumor's power supply. The research was published in Signal Transduction and Targeted Therapy.
The concept builds on years of prior work by the same laboratory, which had previously identified bacterial proteins called cupredoxins as potential cancer suppressors. Earlier peptide drugs from this line of research worked through the p53 gene pathway — but p53 is mutated in a large proportion of cancer patients, limiting the therapy's applicability. The team set out to find a p53-independent approach by searching for bacterial proteins that act directly on mitochondria instead.
To identify candidate proteins, the researchers analyzed tumor tissue from breast cancer patients using DNA sequencing to catalog which bacterial species were present. One species carried a cupredoxin protein called auracyanin, which the team used as the blueprint for aurB. Laboratory experiments confirmed that aurB enters tumor cells, homes in on mitochondria, and binds to ATP synthase — a critical enzyme responsible for producing the cellular energy molecule ATP.
In mouse models of hormone therapy-resistant prostate cancer — a notoriously difficult-to-treat disease — aurB delivered strong results, particularly when paired with radiation therapy. The combination halted tumor growth, suggesting potential for use alongside existing treatments.
Important caveats remain. This is preclinical research, meaning human trials have not yet begun. Results in animal models do not always translate to humans. The full dataset and statistical detail require review of the primary paper. Still, the p53-independent mechanism and mitochondrial targeting strategy represent a meaningful new direction in cancer therapy research.
Key Findings
- Peptide aurB targets ATP synthase in cancer cell mitochondria, cutting off tumor energy production independently of p53.
- aurB was derived from auracyanin, a cupredoxin protein found in bacteria living naturally inside human tumors.
- In preclinical prostate cancer models, aurB combined with radiation effectively halted tumor growth.
- The p53-independent mechanism makes aurB potentially effective for patients whose tumors carry p53 mutations.
- Tumor microbiome bacteria are emerging as a novel source of anticancer drug candidates.
Methodology
This is a news summary based on a peer-reviewed study published in Signal Transduction and Targeted Therapy from the University of Illinois Chicago. Evidence is preclinical, based on cancer cell lines and mouse models of hormone therapy-resistant prostate cancer. Source credibility is high, but the full study should be consulted for statistical detail and methodology.
Study Limitations
This research is preclinical — conducted in cell lines and mouse models — and has not yet been tested in human clinical trials. Animal model results frequently do not replicate in humans. Readers should consult the primary study in Signal Transduction and Targeted Therapy for full methodology, effect sizes, and statistical significance.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: